Assertio (ASRT) Business Payback Period
Assertio Holdings, Inc. (ASRT) manages a diverse portfolio of neurological medications through its US representatives, leveraging the promotion of proven pain relief treatments. The business model is based on physician loyalty and strict DEA oversight of opioids. Growth is driven by mergers with niche brands and partnerships with suppliers. This price chart demonstrates the value of -4.30, visualizing the company's current earnings multiple.
Analytical breakdowns for Assertio Holdings (ASRT)
- price and consensus price forecast:
- market capitalization details:
- book capitalization data:
- company liabilities and liquidity data:
All Debt to Shareholders' Equity Ratio Assertio Holdings, Inc.|ASRT - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Assertio Holdings, Inc.|ASRT - Company Aggregate Debts|Debts to Net Assets Assertio Therapeutics|ASRT - Company Long-Term Debt|Short-Term Debt Assertio|Intermediate Coverage Ratio assertiotx.com
- earnings and market multiples details:
ASRT - Net Profit|Expected Net Income Assertio Holdings, Inc.|ASRT - Price to Earnings Ratio|Projected Price to Earnings Ratio assertiotx.com|ASRT - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Assertio Holdings|ASRT - Operating profit EBITDA|Earnings per share for the last 12 months Assertio|ASRT - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months assertiotx.com|ASRT - Earnings per share growth in current year|Projected earnings per share growth rate for next year Assertio Holdings, Inc.
- company sales and revenue statistics:
Summary company analysis:Assertio Holdings, Inc.
The analyst evaluates the credit profile of Assertio Holdings, Inc. (ASRT) by comparing the business's market value with its net income, which allows for the determination of the investment payback period via the P/E ratio history. Amid pressure from cheap generics and high marketing costs, this indicator reveals the risk of overpaying for the asset, helping to distinguish a favorable entry point from a dangerous decline in fundamental value.
Analysis of competing companies
Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Inhibikase Therapeutics|Cassava (SAVA) - Business Payback Period|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple
